ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners
IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoint’s Biologics and Drug Delivery team on March 1, 2021. Dr. Salegio brings over 19 years of experience in translational neuroscience with direct pre-clinical central nervous system (CNS) expertise in the delivery of therapeutics to the brain and spinal cord, including over 16 years of gene therapy experience working with adeno-associated viral vectors (AAV).
ClearPoint Neuro’s Biologics and Drug Delivery team was established in 2020 to provide turn-key medical device innovation, therapy delivery development and clinical services customized for both pharmaceutical and academic partners working on gene and stem cell therapies to the brain. This team also offers comprehensive services to help its partners navigate existing regulatory guidance and stay abreast of anticipated changes to guidance that will inevitably come.
“Our current and prospective partners working on gene and stem cell therapies have an enormous unmet need for pre-clinical support,” commented Jeremy Stigall, Vice President, Biologics & Drug Delivery Development. “Ernesto’s extensive pre-clinical expertise in the intraparenchymal administration of therapeutics under image-guidance, as well into cerebrospinal fluid (CSF), will allow ClearPoint to add crucial translational consulting services for our biologics partners. When we establish relationships with pharmaceutical partners well before the clinic, ClearPoint products and services can be incorporated throughout the entire development process, delivering consistent, predictable performance, and providing government agencies assurance that the navigation and delivery platform will remain constant from bench-to-bedside. We aim to become their comprehensive medical device partner, allowing them to focus on more traditional pharmaceutical challenges, while ClearPoint delivers state-of-the-art medical device and therapy delivery.”
“I am thrilled to become a member of the ClearPoint team,” commented Dr. Salegio. “After spending almost two decades focusing on translational research, image-guided delivery protocols, complex surgical procedures and in the development of CNS therapies, I am delighted to drive the expansion of ClearPoint’s capabilities. I am eager to leverage their current pre-clinical and clinical portfolio, as well as to their pipeline of innovative tools on the horizon, to provide customized solutions to current and future ClearPoint pharmaceutical partners.”
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States and the EU. The Company’s SmartFlow® cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company’s field-based clinical specialist team which offers support and services for our partners. For more information, please visit www.clearpointneuro.com.
Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Company’s cash resources. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2020, both of which have been filed with the Securities and Exchange Commission, and the Company’s Annual Report on Form 10-K for the year ended December 31 2020, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2021.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States4.3.2021 22:00:00 CET | Press release
► Publication of positive topline results from the NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH and decision to move into pivotal Phase III development ► Breakthrough Therapy Designation granted to lanifibranor in NASH by the U.S. Food and Drug Administration (FDA) ► Finalization of Phase III clinical trial design with lanifibranor in NASH following end-of-phase II meeting with the FDA and receipt of Scientific Advice letter from the European Medicines Agency (EMA) ► Expansion into the United States with appointment of Dr. Michael Cooreman, M.D., as Chief Medical Officer and opening of U.S. subsidiary ► Announcement of timeline for Phase III clinical trial evaluating lanifibranor in NASH ► Confirmation by the FDA that the toxicology package regarding lanifibranor is complete and acceptable to support the filing of a New Drug Application (NDA) for the treatment of NASH and improvement of liver fibrosis ► Completion of World Health Organization’s (WHO) International No
Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report4.3.2021 22:00:00 CET | Press release
Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report Nokia Corporation Stock Exchange Release March 4, 2021 at 23:00 EET Nokia has filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission and published its Nokia in 2020 Annual Report. Espoo, Finland – Nokia has today filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission. Additionally, Nokia has published its Nokia in 2020 Annual Report, which includes audited financial statements, the annual review by the Board of Directors, Nokia’s corporate governance statement and the Remuneration Report for the governing bodies for 2020. The Annual Report on Form 20-F and Nokia in 2020 Annual Report will be available in PDF format at www.nokia.com/about-us/investors/reports-filings, along with Nokia’s past quarterly and annual financial reports. Shareholders may request a hard copy of the reports free of charge through Nok
Appellate Court Hands Momentous Victory to TriMax Over Wickfire4.3.2021 21:35:30 CET | Press release
The Fifth Circuit Court of Appeals issued a decisive ruling that TriMax Media committed no legal violations against Wickfire, L.L.C., while recognizing a jury’s finding that Wickfire intentionally interfered with TriMax’s business. DALLAS, March 04, 2021 (GLOBE NEWSWIRE) -- After seven years of litigation, TriMax has triumphed over Wickfire. On February 26, 2021, an Appellate Court issued a paramount ruling that Wickfire lacked any evidence to support its claims against TriMax. The decision was made in the United States Court of Appeals for the Fifth Circuit, Case Number 17-3043040. The Appellate Court’s ruling reversed all monetary damages previously awarded to Wickfire. The lawsuit, originally before the Western District of Texas, Case No. 14-CV-34, centered around Google AdWords Auctions, an online-auction platform where companies like TriMax and Wickfire compete for advertising space. Wickfire asserted innumerable claims against TriMax, but as to each one, Wickfire ultimately faile
Informa Markets Drives Economic Recovery with Safe and Successful Return to the Show Floor4.3.2021 20:52:58 CET | Press release
Informa Markets makes a customer-driven return to live events, driving economic recovery, connection and innovation through a collaborative and foundational approach to safety ORLANDO, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- As industries and economies around the world look for opportunities to rebuild business in the wake of the COVID-19 pandemic, Informa Markets, a global organizer who creates platforms for a wide range of industries to trade, connect and grow, launched MAGIC Pop-Up Orlando from February 9-11 at the Orange County Convention Center. The ‘Pop-Up’, a smaller scale regional version of their keystone fashion event which typically takes place twice-yearly in Las Vegas, Nevada was a comprehensive ‘one-stop-shop’ opportunity for various segments of the fashion industry, one of the many industries hit hard by the pandemic’s devastating economic impact, to discover new brands, safely network with like-minded retailers, and generate much-needed revenue. Informa Markets Fashion
CoinShares announces outcome of offering in connection with its intended listing on Nasdaq First North Growth Market4.3.2021 20:30:00 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Saint Helier, JERSEY, 4 March, 2021 The subscription period for shares in the initial public offering (the “Offering”) from CoinShares International Limited (“CoinShares” or the “Company”) ended Tuesday, 2 March, 2021. The outcome of the Offering shows that the Offering was subscribed to 447% and that the Company will receive proceeds of SEK 151.1 million before issue costs. The Offering of SEK 151.1 million was covered by subscription commitments of SEK 125.5 million, corresponding to 83% of the total
SpareBank 1 SMN: Notice of meeting of the Supervisory Board on Thursday 25. March 20214.3.2021 20:19:38 CET | Press release
Notice is hereby given of a meeting of the Supervisory Board on Thursday 25. March 2021 at 3pm. The meeting is conducted digitally. See enclosure. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Notice
SpareBank 1 SMN: Innkalling til møte i representantskapet torsdag 25. mars 2021 kl. 15.004.3.2021 20:19:38 CET | Pressemelding
Representantskapets medlemmer i SpareBank 1 SMN innkalles til ordinært representantskapsmøte, torsdag 25. mars kl. 15.00. Møtet gjennomføres digitalt. Se vedlegg. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg Innkalling